Introduction
The fusion of the BCR and ABL genes in Philadelphia chromosome (Ph) positive pluripotent stem cells generates a fatal leukemia termed chronic myelogenous leukemia (CML). The principle driving force responsible for this leukemia is the activated tyrosine kinase of the Bcr-Abl oncoprotein (see review by Arlinghaus, 1998) . The evidence for Bcr-Abl causing this leukemia stems from a number of ®ndings but mainly from studies in two types of mouse animal models. One model involves transplanting Bcr-Abl expressing mouse marrow cells into irradiated recipient mice. Under the appropriate conditions these mice develop a myeloid leukemia in 3 ± 5 weeks (Daley et al., 1990; Gross et al., 1999) . The other model involves generating transgenic mice that express the Bcr-Abl oncoprotein in all tissues (Heisterkamp et al., 1990) . These mice develop acute lymphocytic leukemia shortly after birth. An improved model was developed by placing BCR-ABL under the control of a tetracycline (Tet) repressor promoter system. In this system the P210 Bcr-Abl oncoprotein induces acute leukemia in transgenic mice when mice are maintained without Tet in the drinking water (Huettner et al., 2000) . Importantly, the leukemia was reversible by Tet-controlled repression of BCR-ABL expression.
More recently, a new mouse model has been described for studying CML, which involves intravenous injection of CML cells into radiated NOD/scid mice (Dazzi et al., 1997 (Dazzi et al., , 1998 Lewis et al., 1998) . Optimal engraftment was seen with the lymphoid blast crisis CML cell line BV173. Lewis et al. (1998) was able to engraft primary chronic phase CML cells into 84% of the NOD/scid mice. However, K562 cells, a Bcr-Abl positive myeloid blast CML cell line (Lozzio and Lozzio, 1975) , formed extramedulary tumors with minor marrow involvement (Dazzi et al., 1997) .
We have been investigating the interaction of Bcr and Abl (Arlinghaus, 1998; Ma et al., 1997) . These studies indicate that Bcr and Abl antagonize each other's kinase activity, but by dierent mechanisms. Phosphorylation of Bcr on tyrosine residues inhibits Bcr's serine/threonine kinase activity (Liu et al., 1996b; Wu et al., 1998) , which is evolutionarily diverged from the typical protein kinase (Li et al., 1989; Maru and Witte, 1991) . Additional studies showed that tyrosines 328 and 360 of Bcr are critically involved in regulating Bcr's serine/threonine kinase activity (Wu et al., 1998) . Mutation of tyrosine 360 to phenylalanine (Y360F) sharply reduced Bcr's ability to phosphorylate added substrates (trans-kinase activity) but not its autokinase activity. Similarly, the Y328F mutant had severely reduced transkinase activity but had little eect on its autokinase activity. The Bcr double mutant (Y328F/ Y360F) lacked both transkinase and autokinase activity. These ®ndings indicate that the hydroxyl groups on these two tyrosines are critically involved in regulating the catalytic activity of the Bcr kinase. We have proposed that placing phospho groups on these tyrosines has a similar eect on the kinase activity of Bcr as mutating the tyrosines to phenylalanines (Liu et al., 1996b; Wu et al., 1998) .
In contrast to the eects of Abl on Bcr, Bcr does not appear to phosphorylate the Abl protein. Instead, the phosphoserine form of Bcr binds to the Abl SH2 domain Muller et al., 1991) , which our studies show to be involved in inhibiting the tyrosine kinase activity of either Abl or Bcr-Abl (Liu et al., 1996a; Wu et al., 1999) . Expression of a truncated form of the BCR ®rst exon ] reduced Abl phosphotyrosine content and strongly inhibited the tyrosine kinase activity of Bcr-Abl and c-Abl in protein kinase assays. Furthermore, expression of Bcr(64-413) in K562 cells inhibited growth in a colony assay. Moreover, a phosphoserine containing peptide derived from the serine-rich B box of BCR ®rst exon sequences strongly inhibited the kinase activity of Bcr-Abl (Liu et al., 1996a) .
We have used the Tet repression system to study the eects of Bcr protein expression on the oncogenic eects induced by the Bcr-Abl oncoprotein (Wu et al., 1999) . We inserted the full length BCR gene into a Tet repression vector system, which induced exogenous BCR expression when Tet was removed from the culture medium. Expression of BCR by removing Tet blocked growth of P185 BCR-ABL transformed Rat1 cells in agar. Moreover, the phosphotyrosine content of P185 BCR-ABL and its target proteins was also sharply reduced as a result of the induction of Bcr expression. Similarly, the phosphotyrosine content of P210 BCR-ABL in K562 cells was also reduced by inducing Bcr expression (Wu et al., 1999) .
In this study, we demonstrate that BCR gene expression dramatically altered the pathogenicity of K562 cells in the NOD/scid model. Importantly, the wasting syndrome induced by K6 K562 was inhibited in 80% of the mice. In addition, the wasting syndrome was partially reversed by inducing BCR expression after establishment of disease in engrafted mice. Although the majority of this latter group eventually died, about one-third of these mice demonstrated prolonged survival.
Results
BCR induction generates a kinase-active Bcr containing predominantly phosphoserine with little phosphotyrosine despite the presence of Bcr-Abl in the kinase reaction mixture Our previous studies established an inducible BCR gene expression system in clones of K562 cells containing the Tet-o BCR gene. The BCR Tet-o system is characterized by strong induction of P160 BCR after removal of Tet from the culture medium (Wu et al., 1999) . Importantly, the induced form of Bcr was resistant to tyrosine phosphorylation (Wu et al., 1999) . Induction of BCR expression is controlled by a CMV promoter so as not to compete with the endogenous promoter that drives expression of either the BCR gene or BCR-ABL. Importantly, no evidence of promoter squelching was detected, as BCR induction did not decrease BCR-ABL expression ( Figure  1A ). Release from the Tet block in the Tet-o K6 clone of K562 cells (K6 K562) induced strong expression of Bcr at 8 ± 10 days after removal of Tet from the medium ( Figure 1A ,B). The increase in amounts of Bcr was not the result of loading dierences, as re¯ected by the actin blotting pattern ( Figure 1B ) (Wu et al., 1999) . Of interest, a decrease in Bcr-Abl and Bcr protein formation was routinely observed during the transition period between BCR induction and the time of increased Bcr protein formation. This time period (2 ± 5 days post-induction) coincided with a transient rise in apoptosis as measured by annexin staining (not shown).
Because the induced Bcr protein is resistant to tyrosine phosphorylation (Wu et al., 1999) , we performed a BCR induction experiment to determine whether the induced Bcr protein was active as a serine protein kinase. We assayed the level of Bcr kinase activity in protein complexes containing P160 BCR and P210 BCR-ABL, as described previously (Campbell et al., 1990; Liu et al., 1993) (Figure 1C ). In these experiments, we used a C-terminal Bcr anti-peptide antibody that immunoprecipitates P160 BCR and coprecipitates P210 BCR-ABL that has co-oligomerized with Bcr. At all time points, both Bcr and Bcr-Abl became phosphorylated in the immune complex kinase assay. The induction of BCR expression decreased the autophosphorylation of Bcr-Abl at the 4 and 8 day time points but the level of Bcr-Abl kinase activity recovered by day 10 ( Figure 1C ). However, it should be emphasized that at the time of maximum Bcr expression, phosphorylated Bcr-Abl showed evidence of degradation ( Figure 1C , day 10 ± 12), suggesting that presence of excess Bcr caused degradation of Bcr-Abl complexed to Bcr.
The Bcr serine kinase activity showed a dramatic increase at day 14 after release from the Tet block in transcription ( Figure 1D ), as determined by phosphoamino acid analyses of the Bcr band. At zero time (cells maintained in Tet) and at 2 days in the absence of Tet, the phosphoserine content of P160 BCR was quite low relative to phosphotyrosine ( Figure 1E ), which is consistent with our earlier studies showing that Bcr-Abl phosphorylates Bcr on tyrosine residues (Liu et al., 1993 (Liu et al., , 1996b . However, the amount of phosphoserine Bcr increased at day 4 and decreased somewhat again at day 8 ± 10, but at day 12, the time of major Bcr induction, there was a major shift to phosphoserine Bcr ( Figure 1D ,E), which remained high through day 21 after removal of Tet. The critical values to compare are the ratio of phosphoserine to phosphotyrosine ( Figure 1E ) and not the yield of radioactivity ( Figure 1D ). Thus, when excess Bcr was present, it was considerably more active as a serine/ threonine kinase than the endogenous Bcr protein, as judged by its increased ability to autophosphorylate on serine residues. Similar results were obtained with complexes immunoprecipitated with anti-Bcr(898-911) (the P5C monoclonal antibody (Li et al., 1989) ; not shown), which detects both P160 BCR and P210 BCR-ABL proteins. These results indicate that the excess Bcr protein is resistant to tyrosine phosphorylation by BcrAbl [con®rming our earlier work (Wu et al., 1999) ] and importantly becomes highly active as a serine kinase. Based on our earlier studies (Liu et al., 1996a) , these ®ndings suggest that the induced Bcr, because it is in the phosphoserine form, will antagonize the oncogenic eects of Bcr-Abl.
BCR induction prevents an acute wasting syndrome in NOD/scid mice Because of the results shown in Figure 1 and our ®ndings that induction of Bcr antagonizes the tyrosine kinase and oncogenic eects of Bcr-Abl (Wu et al., 1999) , we wanted to test the leukemogenic potential of the K6 K562 cells in a mouse model. Others have demonstrated the usefulness of the NOD/scid mouse model for leukemia induction (Dazzi et al., 1998; Lewis et al., 1998) , especially for cultured cells that are quite sensitive to natural killer cells like the K562 cell line. A total of 18 mice were injected i.v. with either 2.5610 6 or 7610 6 K6 K562 cells to determine the optimum dose required for inducing a fatal leukemia. This experiment established that 100% of mice (nine mice) fed Tet in their drinking water at levels previously shown to repress Tet controlled gene expression (Huettner et al., 2000) were either terminally ill due to severe wasting syndrome or died within 3 ± 4 weeks. Similar results were obtained with either 2.5610 6 or 7610 6 K6 K562 cells. In contrast mice not fed Tet did not develop the acute wasting syndrome; only two of nine mice (22%) died at 20 days post injection (these mice received 2.5610 6 cells) and the remainder of the mice (seven mice) appeared healthy. Ten of 18 mice (six Tet fed and four not fed Tet) had evidence of K6 K562 engraftment in bone marrow cells as measured by Southern blotting (not shown), despite the ®nding that K562 cells do not eciently home to marrow in such mice (Dazzi et al., 1997) . Similar levels of engraftment were observed with either the higher and lower dose of cells.
A second experiment was conducted with a group of 30 mice in which either one or two million K6 K562 (Campbell et al., 1990; Liu et al., 1993) . (D) Serine kinase activity of P160 BCR is greatly increased following induction of Bcr protein formation. Following separation of the radioactive proteins on the SDS gel shown in panel C, the Bcr band was eluted and assayed for phosphoserine/threonine and phosphotyrosine content. The amount of radioactive phosphoserine and phosphotyrosine shown was determined in a phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA). (E) Graphic representation of the phosphoserine/phosphotyrosine ratio of P160 BCR following Bcr induction. The circles represent the amount of phosphoserine relative to phosphotyrosine in the P160 BCR band. Little phosphothreonine was detected in the samples Oncogene Bcr blocks Bcr-Abl pathogenicity F Lin et al cells were injected. A survival plot indicates that 100% of Tet-fed mice died or were terminally ill within 35 days (Figure 2 ). About 50% of these mice died at 20 days post inoculation. These mice developed a severe and lethal wasting syndrome. The mean survival was 21.55+2.0 days. In contrast, 80% of the mice that were released from the block in BCR transcription at time zero survived and were healthy. Of the two that died, one had clear signs of neoplasia. The remaining eight mice appeared normal after 50 days following injection of K6 K562 cells (Table 1 ). The mean survival was 50.6+2.79 days. The dierence between the mean survival of the Tet versus no Tet groups was signi®cant (P50.0001).
Induction of BCR gene expression after initiating the neoplastic syndrome antagonized the oncogenic effects of Bcr-Abl
Because Bcr induction at day zero within the Bcr-Abl positive K6 K562 cells prevented the acute wasting syndrome in most mice, we determined whether the pathogenic process initiated by injecting K6 K562 cells could be reversed by initiating BCR gene expression during the course of disease development (Figure 2 ). In this experiment, mice were fed Tet for 19 days and then Tet was removed from their drinking water to activate expression of BCR. The survival of mice that remained alive through day 19 was signi®cantly increased ( Figure  2) . The results showed that induction of Bcr delayed death in most mice. Importantly, three of nine mice in this group were alive and appeared healthy at day 48 when these mice were terminated compared to no mouse survival beyond 35 days in the group in which BCR expression was prevented by feeding Tet ( Figure  2 ). The mean survival of this group was 39.22+2.07 days. The dierence between the mean survival of the Tet-fed group (BCR-o) and Tet withdrawal group was signi®cant (P50.0001).
Pathology of mouse tissues following injection of clone K6 K562 cells into NOD/scid mice
The disease syndrome in NOD/scid mice following injection of clone K6 K562 cells exhibited three major pathological phenotypes when the exogenous BCR gene was repressed. One group of mice (Table 1 , T-2 to T-5 and T-11) had severe atrophy of the spleen and/or bone marrow ( Figure 3B ). These mice typically died at an early time (e.g. day 15 ± 17). A second group (Table  1 , T-8 and T-9) had neoplastic spleens ( Figure 3C ), marrow and liver; these mice were quite sick and were sacri®ced at day 34. Of interest, mice injected with 1610 6 million leukemia cells (T-1 through T-5, and T-11) in most cases developed severe atrophy ( Figure 3B ) of the hematopoietic system, whereas those receiving 2610 6 million cells typically developed neoplasia. The third group (T-1, T-6 and T-10) exhibited both neoplastic spleens and/or marrow and atrophy of the hematopoietic system ( Figure 3D ); these mice died at day 18 ± 23. These results suggest the following scenario. Injection of 1610 6 K6 K562 cells in some mice depressed hematopoiesis in the spleen and marrow and caused a severe wasting syndrome, which resulted in early death at 15 ± 17 days after injection. The group receiving 2610 6 cells lived longer (35 days) because hematopoiesis was not repressed but these mice died later due to complications of a neoplasia in spleen and marrow. The third group is of interest because they tend to have both phenotypes and typically died at about 18 ± 21 days.
The pathological status of mice injected with the K6 K562 cells in which the BCR gene was not induced was quite dierent from mice in which the BCR gene was induced at day zero. Eight of the 10 mice in which BCR expression was induced, had no signi®cant microscopic pathological lesions in spleen ( Figure  3E ), marrow and liver (TO-21 to TO-27; TO-30, Table  1 ). These data show that increased BCR gene expression in K6 K562 cells of these mice prevented both the severe wasting syndrome (characterized by depression of hematopoiesis) and neoplasia seen in the liver, spleen and marrow. However, two mice of this group (TO-28 and TO-29) despite inducing BCR gene expression, still died at day 31 ± 34. One of these mice (TO-28) was autopsied and found to have neoplasia of the marrow and atrophy of the marrow as well. This disease phenotype may represent a biological variance in the K6 clone response to BCR gene expression.
The outcome of the group in which BCR expression was induced at day 19 was intermediate in severity compared to the group without BCR induction from day zero (Table 1) . Three mice appeared healthy (TW-16, TW-17 and TW-19, Table 1) at the time of sacri®ce at day 48. One of these mice (TW-16) had a normal spleen and marrow whereas two mice (TW-17 and TW-19) had clear signs of neoplasia. The rest of these mice (six) either died or were sacri®ced at day 35 due to the Cumulative survival data as a Kaplan/Meier plot of mice injected intravenously in the tail vein with K6 K562 cells are shown. To suppress the expression of the BCR gene, the drinking water was supplemented with 1.0 g of tetracycline per liter. Mice not injected with leukemia cells but maintained on Tet at these doses had no visible abnormal eects. At time zero Tet was withdrawn from the water of 10 mice (termed TO mice); at day 19 Tet was withdrawn from a second group of 10 mice (TW); a third group of 10 mice were maintained on Tet from day 0 (T). It must be emphasized that mice dying before day 19 were included in the Tet group wasting syndrome. Mild atrophy of the spleen and marrow was observed in two of these mice (TW-12 and TW-13). Two mice (TW-14 and TW-15) had elevated white counts (5390) for TW-14 and 3520 for TW-15 per ml, respectively with 85 ± 89% segmented neutrophils compared to the normal range of 800 to 1000 white blood cells per ml. These mice appeared to be terminally ill at the time of sacri®ce. The combination of the wasting syndrome and the elevated myeloid cell count suggests an additional outcome of Bcr-Abl expression. Two mice (TW-18 and TW-20) died at day 35 and had signs of disease (neoplastic spleens and marrow as well as atrophy of spleen and marrow).
Mice either fed Tet alone or just irradiated had no evidence of pathology and appeared healthy at the time of sacri®ce at day 50. Three mice fed Tet following radiation treatment also had no evidence of lesions in liver, spleen and marrow at day 34 despite one of these mice suddenly dying at day 34 (results not shown).
Mice injected with K6 K562 cells have BCR-ABL transcripts in their neoplastic tissue RT ± PCR analyses (Lin et al., 1996) was performed on tissues from a third experiment. This experiment consisted of three groups of four to six mice, which were treated identically to those listed in Table 1 . Each mouse was injected with 2610 6 K6 K562 cells. Six of six mice in which BCR expression was not induced had a wasting syndrome and were sacri®ced or died by day 22. Three mice had enlarged spleens and three had normal size spleens but with large nodules. Pathology analyses revealed the same pattern of atrophy of the hematopoietic system or neoplastic spleens or marrow or both. Four of six spleens, two of six marrow samples, one of six liver specimens and six of six lung specimens contained the b3a2 BCR-ABL transcripts (Table 2) . These results clearly establish that engraftment of the K6 K562 cells had occurred and K6 K562 cells were present in the neoplastic tissue. The importance of engraftment in the lungs of these mice is unknown, but no pathological lesions were noted in lung tissue.
None of the Tet withdrawal group (four mice) had a wasting syndrome although two mice suddenly died at 18 ± 21 days. Both of the latter mice had atrophy of the marrow, which was the most likely cause of death. One of these had b3a2 BCR-ABL transcripts in the marrow (Table 2) . Two were sacri®ced on day 23; both had neoplasia in either their spleen or marrow. One had atrophy of the marrow as well. One of these mice had BCR-ABL transcripts in the liver and spleen (Table 2) . Lungs (only three specimens analysed) were negative for BCR-ABL transcripts.
Mice not fed Tet (®ve) had a similar outcome as the second experiment. Four mice were healthy with normal spleens and liver when sacri®ced at 57 days. Their weight was as expected for mice of this age. However, one mouse died at 40 days; it showed evidence of marked atrophy of extramedullary hematopoiesis in the spleen. It had nodules on the spleen, indicative of neoplasia. Only one of these mice (one of the healthy group) had detectable BCR-ABL transcripts and that was in lung tissue (Table 2) . Further studies are needed to determine the fate of K6 K562 cells in which BCR expression is induced. The RT ± PCR data suggests that the K6 K562 cells expressing BCR either died at some point after injection or lost expression of the BCR-ABL oncogene.
Discussion
In this study we established that induction of BCR gene expression in a Bcr-Abl positive cell line (the K562 cell line), previously derived from a CML patient (Lozzio and Lozzio, 1975) , prevented pathogenicity in recipient mice. In these experiments the mice were injected with a clone of K562 cells containing a Tet repressed BCR gene (termed K6 K562 cells). With forced expression of BCR from day zero, 80% of the mice survived and appeared healthy at the time of sacri®ce at day 50 ± 55 ( Figure 2) . No signs of disease were detected in these mice, as pathology studies revealed no evidence of lesions in the spleen, marrow and liver. One mouse died at day 34 with neoplastic marrow and atrophy of the marrow as well (TO-28) ( Table 1) . Another (TO-29) died on a weekend with no data available.
Without forced BCR gene expression, 100% of the mice either died or had a severe wasting syndrome within 35 days after injecting the leukemia cells ( Figure  2 ). This group of mice had several types of abnormal pathology ranging from atrophy of the marrow and spleen to neoplastic involvement of the liver, spleen and marrow or both syndromes. Two of the 10 mice had enlarged spleens (Table 1) . About 50% of the mice died after 20 days.
Induction of BCR gene expression after the disease process was allowed to proceed for 19 days, delayed the fatal eects in those mice that survived beyond the 19 day time point (Figure 2 ). For example for up to 33 days, none of these mice died despite having the disease process underway for 19 days. However, the majority of the mice in this group either died or had terminal illness at about 35 days post inoculation. Importantly, three of nine mice with delayed BCR induction were alive and appeared healthy at day 50, but two of these mice had enlarged spleens, suggesting that they had a more chronic form of disease. Although most of these mice had normal white blood counts, two mice had elevated white blood counts (3000 to 5000/ml). Three of nine mice had enlarged spleens, which were judged to be neoplastic (Table 1) .
The issue of engraftment of K6 K562 cells raises some interesting questions with regards to leukemia induction. Based on the work by Dazzi et al. (1998) , engraftment in the NOD/scid mouse system is a complex phenomenon in which injected cells undergo a crisis followed by repopulation. In the case of K562 Figure 3 Photomicrographs of spleens from NOD/scid mice. (A) Spleen from a mouse that received 2.5 Gy total body irradiation (TBI). The spleen was taken at 21 days. Diuse hypercellularity of the red pulp is due to extensive extramedullary hematopoiesis (EMH) comparable in extent to control mice (E). (B) Spleen from a mouse given TBI, K6 K562 tumor cells, and Tet. Tumors were not found in this animal that developed a`wasting syndrome' clinically, and it had a small spleen that microscopically had near total atrophy of EMH. The spleen was taken at day 13 after injection. (C) Spleen from a mouse given TBI, K6 K562 tumor cells, and Tet. This spleen that was greatly enlarged has diuse replacement by neoplastic cells. This spleen was taken at 22 days after injection from a terminally ill mouse. (D) Spleen from a mouse given TBI, K6 K562 tumor cells, and Tet. This spleen contained a mass of neoplastic cells and the remainder shows atrophy of EMH. This spleen was taken from a mouse who died at 21 days post injection. (E) Spleen from a NOD/scid mouse given K6 K562, which expressed BCR from day zero. The spleen was taken at day 56 post injection. Diuse hypercellularity of the red pulp is due to extensive EMH. Sections were stained with hematoxylin and eosin. The arrows in A and E point to megakaryocytes, which provide evidence of normal hematopoiesis. The`at' identi®es atrophy of the hematopoiesis regions;`tu' identi®es regions that have tumor tissue. Original magni®cation, 6100 cells, the leukemia caused by engraftment in NOD/scid mice predominantly involves extramedulary sites (e.g. spleen and not marrow) (Dazzi et al., 1997) . Our studies have con®rmed these results, as high levels of circulating blood cells were usually not found in K6 K562 injected NOD/scid mice. Therefore, we have elected to not use the term leukemia to describe the syndrome induced by K6 K562 cells. Although some mice had extramedullary tumor involvement, neoplasia was nevertheless detected in marrow of some mice (Table 1) .
In the K6 K562 cell system, when BCR expression was repressed, engraftment was detected in all mice examined as measured by lung tissue analyses with RT ± PCR (Table 2 ). When BCR expression was induced, engraftment was detected in only two of 15 mice by Southern blotting of marrow cells (data not shown) and one of ®ve mice by RT ± PCR (Table 2) . Two of these mice were healthy with no signi®cant microscopic lesions whereas the other had neoplasia in the marrow and died on day 34. Thus, BCR expression may reduce engraftment frequency by reducing cell survival post injection. Of interest, when engraftment is detected in healthy mice receiving K6 K562 cells, we propose that BCR expression has compromised the pathogenic activity of the Bcr-Abl oncoprotein by inhibiting its tyrosine kinase (Liu et al., 1996a; Wu et al., 1999) .
This model system involves intravenous injection of a clone of K562 cells containing a Tet repressed BCR gene, which encodes P160 BCR (Wu et al., 1999) . The repression of BCR transcription is maintained by the Tet o system developed by our colleague Hong-Ji Xu (Hu et al., 1997) . Cells transfected with this plasmid have little expression of the BCR when cells are maintained in Tet. However, when Tet is removed from the culture medium, there is a strong induction of BCR expression in the form of P160 BCR (Wu et al., 1999) . The result of induction of BCR expression is the reduction of phosphotyrosine content of Bcr-Abl (Wu et al., 1999) , the emergence of phosphoserine Bcr resulting from autophosphorylation ( Figure 1D ) and a transient stimulation of apoptosis after 2 ± 5 days of BCR induction (not shown). In ®broblasts transformed by P185 BCR-ABL, the growth of colonies in agar is sharply inhibited following Bcr induction (Wu et al., 1999) . Despite these growth inhibitory eects of excess Bcr in ®broblasts transformed by Bcr-Abl, the K6 K562 cell can be maintained for long periods (e.g. 100 days) after induction of BCR. Thus, the culture system does not manifest changes in the K6 K562 cell induced by BCR expression that are so dramatically observed in the NOD/scid model system. We propose the BCR induction may change cell surface properties of the K6 K562 cell. The growth inhibitory eects of BCR induction are somehow accommodated in the K6 K562 cultured cell system.
Our earlier published ®ndings point to a likely mechanism for Bcr's ability to block the pathogenic eects of Bcr-Abl. These studies support a hypothesis in which the Bcr-Abl tyrosine kinase is strongly inhibited by binding phosphoserine Bcr to the Abl SH2 domain (Liu et al., 1996a) . Studies by others have shown that Bcr-Abl can self-associate to form tetramers (McWhirter et al., 1993) . McWhirter et al. (1993) suggested that Bcr should be able to oligomerize with Bcr-Abl forming mixed tetramers involving the coiled coil domain located within the ®rst 63 amino acids of Bcr. Such mixed tetramers would be expected to have less active tyrosine kinase activity (especially 3 Bcr molecules attached to one Bcr-Abl molecules), as the oligomerization of Bcr-Abl is believed to be the key step required to activate the Abl tyrosine kinase domain. Of interest, we showed that an anti-peptide antibody raised against the C-terminal end of Bcr (which is lacking in Bcr-Abl) co-precipitates Bcr-Abl (Campbell et al., 1990) . This co-oligomerization of Bcr with Bcr-Abl where there is excess Bcr to Bcr-Abl in the oligomer might readily facilitate the binding of Bcr phosphoserine sequences to the Abl SH2 domain, and thus cause inhibition of Bcr-Abl tyrosine kinase activity (Liu et al., 1996a) . Therefore, the increased levels of Bcr will likely result in either the formation of mixed tetramers composed of three Bcr molecules fused to one Bcr-Abl or increased level of Bcr binding to Abl SH2 sequences within Bcr-Abl, or a combination of both. We predict that either result will severely down-regulate the Bcr-Abl tyrosine kinase activity; the higher the molar level of Bcr relative to Bcr-Abl, the more Bcr-Abl kinase inhibition will be achieved. However, we cannot eliminate the possibility that forced expression of Bcr might also interfere with other Bcr-speci®c pathways employed by Bcr-Abl/Bcr complexes (e.g. the Bcr/Raf/14:3:3 translocation to the plasma membrane) (Braselman and McCormick, 1995) . The end result of forced Bcr protein expression could be a combination of either tyrosine kinase inhibition or the inhibition of Bcr-Abl's ability to activate the Ras pathway possibly by way of the Bcr/Raf/14:3:3 pathway or both.
Studies with phosphoserine Bcr peptides have supported the proposed Bcr-Abl kinase inhibition (Hawk et al., 1997) . These ®ndings together with other studies (Liu et al., 1996a; Wu et al., 1999) suggest that Bcr autophosphorylates several serines within the A and B serinerich sequences of Bcr, termed A and B boxes as ®rst identi®ed by Pendergast et al. (1991) . These phosphoserine domains bind tightly to the Abl SH2 domain of Bcr-Abl Muller et al., 1991) , which we propose severely perturbs the catalytic activity of the activated Abl kinase of the Bcr-Abl oncoprotein.
Our ®ndings with the NOD/scid mice further support our hypothesis that Bcr plays an important role in maintaining the chronic phase of CML (Wu et al., 1999) . CML patients typically are diagnosed in a less aggressive phase of the leukemia termed chronic or benign phase. Without treatment, CML patients in benign phase almost always progress to a more aggressive stage called the accelerated phase and then to the terminal stage called blast crisis. Our hypothesis is that Bcr antagonizes the eects of Bcr-Abl in the early stages of CML (Wu et al., 1999) . We further predict that the higher the ratio of Bcr/Bcr-Abl, the more benign the chronic stage. The original Bcr-Abl fusion would represent a functional knockout of one BCR allele, since the Bcr sequences within Bcr-Abl would lack or have greatly reduced ability to autophosphorylate the inhibitory serine residues within the A and B boxes necessary for Bcr-Abl tyrosine kinase inhibition. The inactivation of the Bcr protein serine/threonine kinase encoded by the remaining allele, either by mutation or deletions, would remove the Bcr inhibitory function and allow the Bcr-Abl oncoprotein to be unhindered, resulting in the more aggressive leukemia phenotype typi®ed by the accelerated and/or blast crisis stages.
Materials and methods

Western blotting and protein kinase assays
Western blotting was performed with anti-Bcr(1-16) rabbit antisera (Wu et al., 1999) . Equal amounts of cells were lysed directly in sample buer used for sodium dodecylsulfate (SDS) polyacrylamide gel electrophoresis (PAGE) (Wu et al., 1999) . Blots were processed by ECL methods according to the manufacturer's instructions. Anti-actin (Sigma Chemical Co., St. Louis, MO, USA) was used in blotting the lower portion of the gel as a loading control. Bcr protein kinase assays were performed as described (Liu et al., 1993) . Brie¯y, cells were lysed in a detergent buer and after clari®cation by centrifugation, the lysate was mixed with anti-Bcr(1256-1271) rabbit antiserum, which is directed towards the C-terminus of Bcr. This antibody does not detect Bcr-Abl, because the epitope is lacking in Bcr-Abl. However, it co-precipitates BcrAbl complexed to Bcr (Campbell et al., 1990; Liu et al., 1993) .
NOD/scid mice and Tet vector
NOD/scid mice were injected with a clone (K6) of Bcr-Abl positive K562 cells (Wu et al., 1999) , which was stably transfected with the tetracycline (Tet) repressed CMV promoter vector controlling the expression of an exogenous human BCR gene encoding P160 BCR. The Bcr-Abl oncoprotein is known to be required for cell growth and survival of K562 cells. The Tet vector is termed pEC1217A, which contains the elements of a Tet repressor and a CMV promoter (Hu et al., 1997) . Removal of Tet from the environment allows potent expression of the Tet-repressed gene (Wu et al., 1999) . NOD/scid mice (kindly provided by L Schulz, Jackson Laboratories) were bred and maintained under speci®c pathogen-free conditions in the Barrier Facility within the Center for Comparative Medicine at Baylor College of Medicine (directed by John Belmont, M.D.). The animal experiments were approved by the Animal Care Committee of the Baylor College of Medicine. Six-to eightweek-old mice were sub-lethally irradiated with 250 cGy from a 137Cs source (Nordion, Gammacell 40 at approximately 100 cGy per minute) immediately before tail vein injection of the K6 K562 cells. Animals were euthanized with anesthesia and spleen, liver, and lungs removed for analysis (Table 1) . Bone marrow cells were¯ushed from four bones (tibia and femur). Mice were fed normal chow. To suppress the expression of the BCR gene, the drinking water was supplemented with 1.0 g of Tet per liter. Mice not injected with leukemia cells but maintained on Tet at these doses had no visible abnormal eects. Moreover, irradiated mice had no detectable pathology in liver, spleen and marrow. Sucrose was added to the drinking water of the Tet-fed mice to overcome the bitter taste of Tet.
Southern blotting
High molecular weight DNA was isolated from the bone marrow of the NOD/scid mice using standard methods. EcoRI digests of the genomic DNA (2.5 mg) were loaded in each lane, and the blots were hybridized with the human chromosome 17-speci®c a-satellite probe (p17H8), as previously described (Bonnet and Dick, 1997) . To quantify the presence of human cells, the intensity of the bands was compared with mixtures representing varying ratios of human and mouse DNA made by diluting single reference sources of mouse and human genomic DNA. Sensitivity to 0.1% human DNA was obtained by sucient exposure of the autoradiographs.
RT ± PCR
RT ± PCR was performed as described by Lin et al. (1996) .
Phosphoamino acid analyses
This procedure is performed as described (Liu et al., 1993) on the P160 BCR band labeled with a 32 P-ATP in the Bcr kinase reaction. After separating the proteins by SDS ± PAGE, radioactive Bcr bands were digested with 6 N HCl at 1108C for 90 min as described (Liu et al., 1993) . The hydrolysate was fractionated on thin layer plates to resolve phosphoserine, phosphothreonine and phosphotyrosine. Authentic phosphoamino acids were added and detected by ninhydrin staining.
Pathology analyses
Tissues and marrow were placed in 10% neutral buered formalin (Fisher Scienti®c, Houston, TX, USA) immediately after autopsy. Eye bleeds were taken in EDTA treated tubes for preparing blood smears and performing cell counts. Tissue sections were prepared, H and E stained and analysed by the Department of Veterinary Medicine, M.D. Anderson Cancer Center.
